Cervical Cancer

Obstetrics and Gynecology Clinics of North America

Volumn 39, Issue 2, 2012, Pages 233-253

  Lea, Jayanthi S ^a   Lin, Ken Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; Cervical cancer treatment; Human papillomavirus; Radical hysterectomy

Indexed keywords

CISPLATIN; PACLITAXEL; TOPOTECAN; WART VIRUS VACCINE;

ADENOCARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CIGARETTE SMOKING; COLPOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE SEXUAL DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; INCIDENCE; LYMPH NODE METASTASIS; MOLECULAR PATHOLOGY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PALLIATIVE THERAPY; PAPANICOLAOU TEST; PELVIS TUMOR; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREGNANCY OUTCOME; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; RADICAL TRACHELECTOMY; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; SEXUAL BEHAVIOR; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERUS SURGERY; WART VIRUS;

ADULT; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; HYSTERECTOMY; INCIDENCE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; SMOKING; SOCIOECONOMIC FACTORS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84861520209     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2012.02.008     Document Type: Review

References (81)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Barnholtz-Sloan J., Patel N., Rollison D., et al. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 2009, 20:1129-1138.
3. Wang S.S., Carreon J.D., Gomez S.L., et al. Cervical cancer incidence among 6 Asian ethnic groups in the United States, 1996 through 2004. Cancer 2010, 116(4):949-956.
4. Howe H.L., Wu X., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006, 107(8):1711-1742.
5. Sherman M.E., Wang S.S., Carreon J., et al. Mortality trends for cervical squamous and adenocarcinoma in the United States: relation to incidence and survival. Cancer 2005, 103(6):1258-1264.
6. ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas, number 35, May 2002. Obstet Gynecol 2002, 99(5 Pt 1):855-867. Committee on Practice Bulletins-Gynecology.
7. Datta G.D., Colditz G.A., Kawachi I., et al. Individual-, neighborhood-, and state-level socioeconomic predictors of cervical carcinoma screening among U.S. black women: a multilevel analysis. Cancer 2006, 106(3):664-669.
8. Trimble C.L., Genkinger J.M., Burke A.E., et al. Active and passive cigarette smoking and the risk of cervical neoplasia. Obstet Gynecol 2005, 105(1):174-181.
9. Koshiol J., Schroeder J., Jamieson D.J., et al. Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am J Epidemiol 2006, 164(2):176-183.
10. Plummer M., Herrero R., Franceschi S., et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 2003, 14(9):805-814.
11. Muñoz N., Franceschi S., Bosetti C., et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002, 359(9312):1093-1101.
12. Moreno V., Bosch F.X., Muñoz N., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002, 359(9312):1085-1092.
13. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2007, 120:885-891. The International Collaboration of Epidemiological Studies of Cervical Cancer.
14. Benoit A.G., Krepart G.V., Lotocki R.J. Results of prior cytologic screening in patients with a diagnosis of stage I carcinoma of the cervix. Am J Obstet Gynecol 1984, 148(5):690-694.
15. Bosch F.X., Muñoz N. The viral etiology of cervical cancer. Virus Res 2002, 89(2):183-190.
16. Jones D.L., Münger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 1997, 71(4):2905-2912.
17. Jones E.E., Wells S.I. Cervical cancer and human papillomaviruses: inactivation of retinoblastoma and other tumor suppressor pathways. Curr Mol Med 2006, 6(7):795-808.
18. Helt A.M., Funk J.O., Galloway D.A. Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J Virol 2002, 76(20):10559-10568.
19. Wentzensen N., Vinokurova S., von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004, 64(11):3878-3884.
20. Fader A.N., Edwards R.P., Cost M., et al. Sentinel lymph node biopsy in early-stage cervical cancer: utility of intraoperative versus postoperative assessment. Gynecol Oncol 2008, 111(1):13-17.
21. Cormier B., Diaz J.P., Shih K., et al. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol 2011, 122(2):275-280.
22. Alfsen G.C., Kristensen G.B., Skovlund E., et al. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer 2001, 92(9):2471-2483.
23. Grigsby P.W., Perez C.A., Kuske R.R., et al. Adenocarcinoma of the uterine cervix: lack of evidence for a poor prognosis. Radiother Oncol 1988, 12(4):289-296.
24. Kilgore L.C., Soong S.J., Gore H., et al. Analysis of prognostic features in adenocarcinoma of the cervix. Gynecol Oncol 1988, 31(1):137-153.
25. Lee K.B., Lee J.M., Park C.Y., et al. What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix?. A matched case-control study. Int J Gynecol Cancer 2006, 16(4):1569-1573.
26. Davy M.L., Dodd T.J., Luke C.G., et al. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol 2003, 101(1):38-45.
27. Eifel P.J., Burke T.W., Morris M., et al. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995, 59(1):38-44.
28. Eifel P.J., Morris M., Oswald M.J., et al. Adenocarcinoma of the uterine cervix: prognosis and patterns of failure in 367 cases. Cancer 1990, 65(11):2507-2514.
29. Hopkins M.P., Morley G.W. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 1991, 77(6):912-917.
30. Lai C.H., Hsueh S., Hong J.H., et al. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery?. Int J Gynecol Cancer 1999, 9(1):28-36.
31. Lee Y.Y., Choi C.H., Kim T.J., et al. A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol 2011, 120(3):439-443.
32. Macdonald O.K., Chen J., Dodson M., et al. Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix. Am J Clin Oncol 2009, 32(4):411-416.
33. McCusker M.E., Coté T.R., Clegg L.X., et al. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol 2003, 88(3):333-339.
34. Chen J., Macdonald O.K., Gaffney D.K. Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol 2008, 111(6):1394-1402.
35. Pecorelli S., Zigliani L., Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009, 105(2):107-108.
36. Benedet J.L., Bender H., Jones H., et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000, 70(2):209-262.
37. Lagasse L.D., Creasman W.T., Shingleton H.M., et al. Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecol Oncol 1980, 9(1):90-98.
38. Mitchell D.G., Snyder B., Coakley F., et al. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol 2006, 24(36):5687-5694.
39. Sahdev A., Sohaib S.A., Wenaden A.E., et al. The performance of magnetic resonance imaging in early cervical carcinoma: a long-term experience. Int J Gynecol Cancer 2007, 17(3):629-636.
40. Rajendran J.G., Greer B.E. Expanding role of positron emission tomography in cancer of the uterine cervix. J Natl Compr Canc Netw 2006, 4(5):463-469.
41. Wolfson A.H. Magnetic resonance imaging and positron-emission tomography imaging in the 21st century as tools for the evaluation and management of patients with invasive cervical carcinoma. Semin Radiat Oncol 2006, 16(3):186-191.
42. Lin W.C., Hung Y.C., Yeh L.S., et al. Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings. Gynecol Oncol 2003, 89(1):73-76.
43. Rose P.G., Adler L.P., Rodriguez M., et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999, 17(1):41-45.
44. Yen T.C., Ng K.K., Ma S.Y., et al. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol 2003, 21(19):3651-3658.
45. Amit A., Beck D., Lowenstein L., et al. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecol Oncol 2006, 100(1):65-69.
46. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy. J Clin Oncol 2006, 24(1):123-128.
47. 18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer 2005, 104(11):2484-2491.
48. Loft A., Berthelsen A.K., Roed H., et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 2007, 106(1):29-34.
49. Östör A.G., Rome R.M. Micro-invasive squamous cell carcinoma of the cervix: a clinico-pathologic study of 200 cases with long-term follow-up. Int J Gynecol Cancer 1994, 4(4):257-264.
50. Landoni F., Maneo A., Colombo A., et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997, 350(9077):535-540.
51. Sutton G.P., Bundy B.N., Delgado G., et al. Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992, 166(1 Pt 1):50-53.
52. Landoni F., Maneo A., Cormio G., et al. Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. Gynecol Oncol 2001, 80(1):3-12.
53. Diaz J.P., Sonoda Y., Leitao M.M., et al. Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecol Oncol 2008, 111(2):255-260.
54. Abu-Rustum N.R., Sonoda Y., Black D., et al. Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecol Oncol 2006, 103(3):807-813.
55. Abu-Rustum N.R., Neubauer N., Sonoda Y., et al. Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecol Oncol 2008, 111(2):261-264.
56. Sedlis A., Bundy B.N., Rotman M.Z., et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol 1999, 73(2):177-183.
57. Peters W.A., Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000, 18(8):1606-1613.
58. Rose P.G., Adler L.P., Rodriguez M., et al. Positron emission tomography for evaluating para aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999, 17(1):41-45.
59. Whitney C.W., Sause W., Bundy B.N., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999, 17(5):1339-1348.
60. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999, 340(15):1137-1143.
61. Dueñas-González A., Zarbá J.J., Patel F., et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011, 29(13):1678-1685.
62. Hacker N.F., Wain G.V., Nicklin J.L. Resection of bulky positive lymph nodes in patients with cervical carcinoma. Int J Gynecol Cancer 1995, 5(4):250-256.
63. Holcomb K., Abulafia O., Matthews R.P., et al. The impact of pretreatment staging laparotomy on survival in locally advanced cervical carcinoma. Eur J Gynaecol Oncol 1999, 20(2):90-93.
64. Cosin J.A., Fowler J.M., Chen M.D., et al. Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. Cancer 1998, 82(11):2241-2248.
65. Kupets R., Thomas G.M., Covens A. Is there a role for pelvic lymph node debulking in advanced cervical cancer?. Gynecol Oncol 2002, 87(2):163-170.
66. Petereit D.G., Hartenback E.M., Thomas G.M. Para-aortic lymph node evaluation in cervical cancer: the impact of staging upon treatment decisions and outcome. Int J Gynecol Cancer 1998, 8:353-364.
67. Coleman R.L., Keeney E.D., Freedman R.S., et al. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol 1994, 55(1):29-35.
68. Ijaz T., Eifel P.J., Burke T., et al. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma. Gynecol Oncol 1998, 70(2):241-246.
69. Ito H., Shigematsu N., Kawada T., et al. Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy. Gynecol Oncol 1997, 67(2):154-161.
70. Lanciano R. Radiotherapy for the treatment of locally recurrent cervical cancer. J Natl Cancer Inst Monogr 1996, (21):113-115.
71. Potter M.E., Alvarez R.D., Gay F.L., et al. Optimal therapy for pelvic recurrence after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol 1990, 37(1):74-77.
72. Thigpen J.T., Vance R., Puneky L., et al. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol 1995, 22(2 Suppl 3):16-24.
73. Vermorken J.B. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review. Int J Gynecol Cancer 1993, 3(3):129-142.
74. Münstedt K., Johnson P., von Georgi R., et al. Consequences of inadvertent, suboptimal primary surgery in carcinoma of the uterine cervix. Gynecol Oncol 2004, 94(2):515-520.
75. Moore D.H., Blessing J.A., McQuellon R.P., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004, 22(15):3113.
76. Long H.J., Bundy B.N., Grendys E.C., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005, 23(21):4626.
77. Morris M., Blessing J.A., Monk B.J., et al. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004, 22(16):3340.
78. Brewer C.A., Blessing J.A., Nagourney R.A., et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006, 100(2):385.
79. Grigsby P.W., Perez C.A. Radiotherapy alone for medically inoperable carcinoma of the cervix: stage IA and carcinoma in situ. Int J Radiat Oncol Biol Phys 1991, 21(2):375.
80. Komaki R., Brickner T.J., Hanlon A.L., et al. Long-term results of treatment of cervical carcinoma in the United States in 1973, 1978, and 1983: Patterns of Care Study (PCS). Int J Radiat Oncol Biol Phys 1995, 31(4):973.
81. Webb M.J., Symmonds R.E. Site of recurrence of cervical cancer after radical hysterectomy. Am J Obstet Gynecol 1980, 138(7 Pt 1):813-817.